MERCK
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
De’Longhi Launches the Perfetto 3.0 Global Campaign Starring Brad Pitt to Solidify Its Worldwide Coffee Leadership8.9.2025 19:43:00 CEST | Press release
Premiered at the Venice Film Festival, the new campaign captures the emotions and experience of the Perfetto coffee ritual De’Longhi has launched its third global campaign centered on the world of coffee on the occasion of the 82nd Venice Film Festival, where the brand is a supporter and present with special activations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908690655/en/ Brad drinking coffee The new campaign reflects De’Longhi’s continued evolution into alifestyle brand rooted in Italian design and innovation. This 3rd chapter builds upon a proven track record from recent years, which has supported the Group in growing the business and solidifying its market leadership. This campaign is set to be the Group's most extensive to date, with significant consumer reach across all traditional, digital, and social media channels, engaging and targeting the broadest possible audience among coffee lovers and prospective c
Second Front Systems to Launch Game Warden® Platform on AWS European Sovereign Cloud8.9.2025 18:31:00 CEST | Press release
Availability on AWS European Sovereign Cloud will enable accelerated ISV compliance and deployment while meeting stringent data sovereignty requirements. Second Front Systems (2F), a Technology Partner in the Amazon Web Services (AWS) Partner Network (APN), today announced that its 2F Game Warden® platform will be available on AWS European Sovereign Cloud. The announcement builds on Second Front's deep technical expertise and proven customer success in delivering security solutions on AWS. Organizations across Europe face complex regulatory requirements, including Germany's C5, and the EU's Digital Operational Resilience Act (DORA) and NIS2 Directive. The availability of 2F Game Warden on AWS European Sovereign Cloud provides a pre-validated solution that helps customers meet these stringent compliance requirements while maintaining data residency within EU borders. “Digital sovereignty isn’t just about compliance—it’s about building trust and resilience,” said Tyler Sweatt, CEO of Sec
Experian Ranked 6th in 2025 IDC FinTech Rankings: Top 1008.9.2025 18:15:00 CEST | Press release
Places in the top-10 global technology providers for the fourth consecutive year Experian today announced that it was ranked 6th in the 2025 IDC FinTech Rankings: Top 100, rising one spot from last year’s rankings and placing in the top-10 global technology providers for the fourth consecutive year. The FinTech Rankings feature enterprise companies from around the world that serve multiple industries and generate significant revenues from the financial services and FinTech industries. “Experian helps financial services organizations tackle their toughest business challenges by delivering continuous innovation in AI decisioning, advanced analytics, and fraud prevention,” said Alex Lintner, CEO of Experian Technology & Software. “As one of the world’s largest FinTech companies, this recognition underscores how we empower customers globally to accelerate operations, expand financial inclusion, reduce risk with transformative AI, and ultimately drive stronger business results.” A prime exa
Balsam Hill Proudly Announces Its Commitment to a More Sustainable Christmas Tree8.9.2025 18:00:00 CEST | Press release
Balsam Hill®, the global leader in high-quality, true-to-nature, reusable, artificial Christmas trees and holiday décor, proudly announces an innovation in how its heirloom-quality Christmas trees are now being made using more sustainable materials. Since 2006, Balsam Hill has been committed to reusability, quality, realism, and innovation in the Christmas trees its millions of customers have come to love. In that spirit, Balsam Hill is proud to be the first retailer in the world to offer Christmas trees with True Needle® tips made with plant-based polyethylene, derived from sugarcane, not fossil fuels. And just as exciting, as of the holiday 2025 season production line, all the brand’s other True Needle trees will now incorporate 30% post-consumer GRS-certified recycled polyethylene made from tear-away water bottle caps. Both changes were made without sacrificing the quality controls and safety considerations required for each Balsam Hill tree, including the company’s three-year warra
Xsolla and Global Game Jam Announce a New Webinar to Help Indie Developers Grow Player Bases and Generate First Sales for Their Games8.9.2025 18:00:00 CEST | Press release
Practical Strategies For Attracting Players And Monetizing Games Will Be Shared In A Live Panel Featuring Xsolla Leaders, Game Developers, And Industry Experts Xsolla, a leading global video game commerce company, announces a new collaboration with Global Game Jam (GGJ) to host a live webinar for indie developers titled “From Zero to 1K: Growing Your Player Base and Making Your First $$.” The session will take place on Tuesday, September 9, 2025, at 10:00 AM PT, offering actionable strategies to help developers attract their first audience and begin generating sustainable revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908673871/en/ (Graphic: Xsolla) Bringing together game industry leaders and experienced developers, the event will provide beginner-friendly insights on how to make a game appealing to players while establishing effective monetization tactics. Attendees will learn how to avoid common early mistakes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom